GRF6021

GRF6021 is a proprietary, human plasma-derived therapeutic fraction developed by Alkahest (a subsidiary of Grifols) for the treatment of neurodegenerative and age-related inflammatory conditions. It is designed to modulate biological pathways associated with aging, specifically targeting intracellular signaling cascades in blood leukocytes to reduce systemic inflammation. The drug has been evaluated in Phase II clinical trials for Parkinson's disease with cognitive impairment and for its potential to improve postoperative recovery and reduce inflammation in patients undergoing primary hip or knee arthroplasty. The development of GRF6021 is part of a broader research collaboration focused on identifying chronofactors in human plasma that can be utilized to treat age-related diseases.